HomePink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo
Email Preferences
Free Trial
Email Preferences
Free Trial
Spotlight
  • China
  • Obesity
  • AI
  • Drug Pricing
  • Cell & Gene Therapies

Business
  • Deals
  • Financing
  • Earnings
  • Commercial Strategy
  • Approvals & Launches
  • Trial Results
  • Market Access
Disease
  • Cancer
  • Immune Disorders
  • Cardiovascular
  • Neurological
  • Rare Diseases

Deep Dives
  • Interviews
  • Data Insights
  • Scrip Asks
  • Disease Landscapes
Focus On Asia
  • Japan
  • South Korea
  • India
  • Scrip Asia 100

Tools & Trackers
  • Pipeline Watch
  • Finance Watch
  • Deal Watch
  • Stock Watch
  • Top Selling Drugs
  • Company Rankings
  • Executive Moves
Podcasts

Conference Coverage

Partner Insights

Scrip Perspectives

Previewing biopharma commercial, market access and development themes.

View

Pink Sheet

Scrip

Medtech Insight

HBW Insight

Generics Bulletin

In Vivo
Scrip logo
  1. Home
  2. >>Scrip
  3. >>Disease
  4. >>Cancer

Cancer

Immuno-oncology
  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Dec 05 2025 
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

    Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

    Nov 12 2025

    Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Nov 12 2025

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Allarity Hopes To Breathe New Life Into Ixempra In Breast Cancer

    Allarity Hopes To Breathe New Life Into Ixempra In Breast Cancer

    Sep 24 2025

    The US precision medicine company hopes its drug response predictor technology will enhance responses to the chemotherapy Ixempra on the basis of promising data from a handful of breast cancer patients in a Phase II trial, marking a positive turn in its journey to date.  


  • Innovent/GenFleet Score China’s First KRAS G12C Inhibitor Approval

    Innovent/GenFleet Score China’s First KRAS G12C Inhibitor Approval

    Mar 10 2025 
    • By Dexter Jie Yan

    The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.

  • Cagrisema Leads The Charge For 2025

    Cagrisema Leads The Charge For 2025

    Mar 10 2025 
    • By Elizabeth Cairns

    2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

  • Ordspono Will Be Regeneron’s First Independent European Launch

    Ordspono Will Be Regeneron’s First Independent European Launch

    Mar 10 2025 
    • By Jessica Merrill

    Ordspono, a bispecific antibody newly approved in the EU to treat follicular lymphoma and diffuse large B-cell lymphoma, joins Libtayo in Regeneron’s growing oncology portfolio.

  • What To Look Out For At ESMO 2024

    What To Look Out For At ESMO 2024

    Mar 10 2025 
    • By Alexandra Shimmings

    Attendees at this year's European Society for Medical Oncology meeting in Barcelona can look forward to a range of interesting datasets, from Phase III trials of established products in new settings to preliminary studies of novel products coming through the pipeline.  


  • Pierre Fabre Pushes To Be Partner Of Choice For Budding Biotechs

    Pierre Fabre Pushes To Be Partner Of Choice For Budding Biotechs

    Mar 10 2025 
    • By Kevin Grogan

    Francesco Hofmann, head of R&D at the mid-sized French group, tells Scrip that its strategy of not playing in the spaces that are dominated by big pharma is paying off.

  • As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS

    As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS

    Mar 10 2025 
    • By Mandy Jackson

    Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.

  • Novo Nordisk’s Semaglutide Shows Promise In Hidradenitis Suppurativa

    Novo Nordisk’s Semaglutide Shows Promise In Hidradenitis Suppurativa

    Mar 10 2025 
    • By Andrew McConaghie

    An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.

  • ESMO 24: SunRISes On J&J’s TAR-200 In Bladder Cancer

    ESMO 24: SunRISes On J&J’s TAR-200 In Bladder Cancer

    Sep 26 2024 
    • By Alexandra Shimmings

    J&J acquired Taris in 2019 to gain access to TAR-200 and its drug delivery platform. Now, early clinical data suggest the product could delay or remove the need for cystectomy in several bladder cancer settings and the US healthcare giant is eyeing multi-blockbuster sales.    


  • pipeline watch test

    pipeline watch test

    Sep 25 2024 
    • By Alexandra Shimmings

  • ESMO 24: CDK2 Inhibitors - Where Next For The Novel Class?

    ESMO 24: CDK2 Inhibitors - Where Next For The Novel Class?

    Sep 19 2024 
    • By Alexandra Shimmings

    The Barcelona meeting saw early data from two candidates from Incyte and Pfizer which suggest some progress for a new drug mechanism that has so far underwhelmed.    

  • ESMO 24: Butterfly Effect? J&J’s Rybrevant Looks Beyond Lung Cancer

    ESMO 24: Butterfly Effect? J&J’s Rybrevant Looks Beyond Lung Cancer

    Sep 17 2024 
    • By Alexandra Shimmings

    New Phase II data for the bispecific antibody show promise in colorectal cancer as the company seeks to spread the bispecific antibody’s wings. Phase III trials are on the horizon, where it will need to go up against standard of care.    

  • ESMO 24: NIAGARA – Trial Design Question Hangs Over Imfinzi’s Bladder Cancer Return

    ESMO 24: NIAGARA – Trial Design Question Hangs Over Imfinzi’s Bladder Cancer Return

    Sep 16 2024 
    • By Alexandra Shimmings

    AstraZeneca’s NIAGARA trial of perioperative Imfinzi in bladder cancer was positively received at the ESMO meeting but its design did not distinguish the contributions of each treatment portion to the overall effect – something that the US FDA is likely to have a view on.    


  • ESMO 24: Incyte’s Zynyz Finally Mounts The POD1UM

    ESMO 24: Incyte’s Zynyz Finally Mounts The POD1UM

    Sep 15 2024 
    • By Alexandra Shimmings

    Persistence has paid off for Incyte’s Zynyz in anal cancer with a Phase III win that should make up for a previous disappointment at the FDA and give a boost to the firm’s pipeline prospects for a post-Jakafi era.    

  • New Domestic Partnerships Help DualityBio Become China ADC Bellwether

    New Domestic Partnerships Help DualityBio Become China ADC Bellwether

    Sep 04 2024 
    • By Dexter Jie Yan

    China's Duality Biologics, founded in 2020, has developed two-thirds of its clinical-stage antibody-drug conjugates by combining antibodies acquired from domestic peers with its proprietary linker-payload platform.

  • Quick Listen: Scrip's Five Must-Know Things

    Quick Listen: Scrip's Five Must-Know Things

    Aug 26 2024 
    • By Ian Haydock

    In this week's podcast edition of Five Must-Know Things: CMS’s price reveal better than expected?; new diabetes risk data for Zepbound; can J&J’s lung cancer combo stand up to Tagrisso?; new recruits for BioMarin leadership; and Glenmark’s shifting revenues.

  • Five Recent Deals Show ADCs Aren’t Cooling Off For Summer

    Five Recent Deals Show ADCs Aren’t Cooling Off For Summer

    Aug 23 2024 
    • By Joseph Haas

    While 2024 has seen two buyouts of antibody-drug conjugate specialists with $1bn-plus price tags, the focus on ADCs has continued, accounting for almost half of recent oncology deals.

Norstella India logo
Twitter feedfooter-block.linkedin-linkRSS feedPodcastPodcast

About

  • About UsOpens in new window
  • Meet the Team
  • AdvertiseOpens in new window
  • Contact Us

Account

  • My Account
  • My View
  • Email Preferences
  • Start Free TrialOpens in new window

More

  • Scrip Perspectives
  • Scrip 100 Ranking
  • Scrip Asia 100
  • Conferences
  • Executives On The Move
  • Pipeline Watch
Home
Terms and ConditionsOpens in new window
Privacy PolicyOpens in new window